UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 825

Sortiert nach

Kidney Transplant Recipients Carrying the CYP3A422 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations

American journal of transplantation, 2015-03, Vol.15 (3), p.800-805

2015

Volltextzugriff (PDF)

The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients

British journal of clinical pharmacology, 2019-03, Vol.85 (3), p.516-529

2019

Volltextzugriff (PDF)

Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients

British journal of clinical pharmacology, 2014-08, Vol.78 (2), p.364-372

2014

Volltextzugriff (PDF)

Association of donor small ubiquitin‐like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation

Liver international, 2018-04, Vol.38 (4), p.724-732

2018

Volltextzugriff (PDF)

Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients

Transplant immunology, 2012-08, Vol.27 (1), p.12-18

2012

Volltextzugriff (PDF)

Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients

European journal of clinical pharmacology, 2015-02, Vol.71 (2), p.191-198

2015

Volltextzugriff (PDF)

Association of Hemoglobin Levels, CYP3A5, and NR1I3 Gene Polymorphisms with Tacrolimus Pharmacokinetics in Liver Transplant Patients

Drug metabolism and pharmacokinetics, 2014, Vol.29 (3), p.249-253

2014

Volltextzugriff (PDF)

Pharmacokinetics for Once‐ Versus Twice‐Daily Tacrolimus Formulations in De Novo Kidney Transplantation: A Randomized, Open‐Label Trial

American journal of transplantation, 2009-11, Vol.9 (11), p.2505-2513

2009

Volltextzugriff (PDF)

Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus

Transplantation, 2005-11, Vol.80 (10), p.1419

2005

Volltextzugriff (PDF)

A Steady‐State Head‐to‐Head Pharmacokinetic Comparison of All FK‐506 (Tacrolimus) Formulations (ASTCOFF): An Open‐Label, Prospective, Randomized, Two‐Arm, Three‐Period Crossover Study

American journal of transplantation, 2017-02, Vol.17 (2), p.432-442

2017

Volltextzugriff (PDF)

High tacrolimus trough level variability is associated with rejections after heart transplant

American journal of transplantation, 2018-10, Vol.18 (10), p.2571-2578

2018

Volltextzugriff (PDF)

Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure

Kidney international, 2014-06, Vol.85 (6), p.1404-1411

2014

Volltextzugriff (PDF)

Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir

American journal of transplantation, 2015-05, Vol.15 (5), p.1313-1322

2015

Volltextzugriff (PDF)

Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Clinical and Genetic Factors and Associated With Acute Kidney Injury

Clinical pharmacology and therapeutics, 2020-02, Vol.107 (2), p.462-470

2020

Volltextzugriff (PDF)

Genotype‐Guided Model for Prediction of Tacrolimus Initial Dosing After Lung Transplantation

Journal of clinical pharmacology, 2024-06, Vol.64 (6), p.719-727

2024

Volltextzugriff (PDF)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients

European journal of clinical pharmacology, 2014-06, Vol.70 (6), p.685-693

2014

Volltextzugriff (PDF)

Excess fluid distribution affects tacrolimus absorption in peritoneal dialysis patients

Clinical and experimental nephrology, 2013-10, Vol.17 (5), p.743-749

2013

Volltextzugriff (PDF)

Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing

Clinical pharmacology and therapeutics, 2010-06, Vol.87 (6), p.721-726

2010

Volltextzugriff (PDF)

The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival

Transplantation, 2020-06, Vol.104 (6), p.1263

2020

Volltextzugriff (PDF)

Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation

Transplantation, 2017-12, Vol.101 (12), p.2931

2017

Volltextzugriff (PDF)

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients

British journal of clinical pharmacology, 2019-03, Vol.85 (3), p.601-615

2019

Volltextzugriff (PDF)

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

Hepatology (Baltimore, Md.), 2011-07, Vol.54 (1), p.20-27

2011

Volltextzugriff (PDF)

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients

The Annals of pharmacotherapy, 2024-06, Vol.58 (6), p.605

2024

Volltextzugriff (PDF)

Importance of hematocrit for a tacrolimus target concentration strategy

European journal of clinical pharmacology, 2014-01, Vol.70 (1), p.65-77

2014

Volltextzugriff (PDF)

Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit

British journal of clinical pharmacology, 2015-09, Vol.80 (3), p.548-559

2015

Volltextzugriff (PDF)

1 – 25 von 825

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(796)
Mit Volltextzugriff
(604)

Publikationsform

Artikel
(825)

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(825)
Science & Technology
(778)
Life Sciences & Biomedicine
(766)
Male
(763)
Female
(732)
Adult
(685)
Tacrolimus - Pharmacokinetics
(653)
Immunosuppressive Agents - Pharmacokinetics
(632)
Tacrolimus
(423)
Tacrolimus - Administration & Dosage
(390)
Pharmacology & Pharmacy
(373)
Biological And Medical Sciences
(365)
Medical Sciences
(364)
Immunosuppressive Agents - Administration & Dosage
(358)
Transplantation
(346)
Aged
(326)
Kidney Transplantation
(301)
Pharmacology. Drug Treatments
(290)
Tacrolimus - Therapeutic Use
(267)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Kidney Transplant Recipients Carrying the CYP3A422 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations

The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients

Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients

Association of donor small ubiquitin‐like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation

Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients

Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients

Association of Hemoglobin Levels, CYP3A5, and NR1I3 Gene Polymorphisms with Tacrolimus Pharmacokinetics in Liver Transplant Patients

Pharmacokinetics for Once‐ Versus Twice‐Daily Tacrolimus Formulations in De Novo Kidney Transplantation: A Randomized, Open‐Label Trial

Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus

A Steady‐State Head‐to‐Head Pharmacokinetic Comparison of All FK‐506 (Tacrolimus) Formulations (ASTCOFF): An Open‐Label, Prospective, Randomized, Two‐Arm, Three‐Period Crossover Study

High tacrolimus trough level variability is associated with rejections after heart transplant

Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure

Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir

Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Clinical and Genetic Factors and Associated With Acute Kidney Injury

Genotype‐Guided Model for Prediction of Tacrolimus Initial Dosing After Lung Transplantation

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients

Excess fluid distribution affects tacrolimus absorption in peritoneal dialysis patients

Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing

The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival

Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients

Importance of hematocrit for a tacrolimus target concentration strategy

Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit

Aktive Filter

Suchergebnisse filtern